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Current guidelines recommend that all cirrhotic patients should undergo screening endoscopy at diagnosis to identify patients with
varices at high risk of bleeding who will benefit from primary prophylaxis. This approach places a heavy burden upon endoscopy
units and the repeated testing over timemay have a detrimental eﬀect on patient compliance. Noninvasive identification of patients
at highest risk for oesophageal varices would limit investigation to those most likely to benefit. Upper GI endoscopy is deemed to
be the gold standard against which all other tests are compared, but is not without its limitations. Multiple studies have been
performed assessing clinical signs and variables relating to liver function, variables relating to liver fibrosis, and also to portal
hypertension and hypersplenism. Whilst some tests are clearly preferable to patients, none appear to be as accurate as upper GI
endoscopy in the diagnosis of oesophageal varices. The search for noninvasive tests continues.
1. Introduction
Cirrhosis is the end stage of every chronic liver disease,
resulting in formation of fibrous tissue, disorganization of
liver architecture, and nodule formation, which interferes
with liver function and results in portal hypertension. Portal
hypertension is associated with development of a hyperdy-
namic circulation and complications such as ascites, hepatic
encephalopathy, and oesophago-gastric varices. Patients with
cirrhosis and gastro-oesophageal varices have a hepatic
venous pressure gradient during haemodynamic catheter-
ization of at least 10–12mmHg [1]. Oesophageal varices
are present at diagnosis in approximately 50% of cirrhotic
patients, being more common in Child-Pugh class C patients
compared to Child-Pugh class A patients (85% versus 40%)
[1, 2]. De novo formation of varices occurs at a rate of 5%
per year, with a higher incidence in patients continuing to
consume alcohol or with worsening liver function [2]. Once
varices form, they enlarge from small to large at a rate of
5–12% per year [2] and bleed at a rate of 5–15% per year.
The greatest bleeding risk is seen in large varices classified as
being >5mm diameter and is also influenced by liver disease
severity as assessed by Child-Pugh score, and by the presence
of red wale markings on varices at endoscopy. Therefore,
these factors should also be taken into consideration to
classify “high-risk varices” [3].
Reports from the 1940’s to the 1980’s demonstrate
poor outcomes from variceal bleeding with mortality rates
between 30–60% [4–6], but studies suggest that the out-
comes have improved over the last few decades [7–9]. This
is demonstrated in a study by Carbonell et al. [10], who
showed that between 1980–2000, the inhospital mortality
from variceal bleeding decreased from 42.6% to 14.5%
and was associated with decreased rebleeding and rates of
bacterial infection.
Although mortality from a bleeding episode has de-
creased with improved endoscopic and radiological tech-
niques together with new pharmacologic therapies, a 20–
30% mortality [11] means that bleeding from oesophageal
varices remains of significant clinical importance. Early
diagnosis of varices before the first bleed is essential as
studies of primary prophylaxis clearly show that the risk
of variceal haemorrhage can be reduced by 50% to about
15% for large oesophageal varices [12]. Current guidelines,
therefore, recommend that all cirrhotic patients should be
screened for varices at diagnosis, with followup every 2-
3 years for patients without varices (depending upon liver
disease severity) and 1-2 years for patients with small varices,
to assess for enlargement of varices and need for prophylactic
treatment [13]. Upper GI endoscopy remains the gold
standard for screening, but this test is not without its own
limitations. There is conflicting evidence with regard to the
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interobserver agreement for endoscopic diagnosis of variceal
presence, grade, or presence of red signs [14–16]. Cales et al.
found in 100 cirrhotic patients that the interobserver agree-
ment between four independent observers for the size of
oesophageal varices and presence of red signs was good with
kappa values of 0.59 and 0.60, respectively. However, Bendt-
sen et al. found considerable variation in the interobserver
agreement on the diagnosis and grading of oesophageal
varices between 22 endoscopists with a large variation in
kappa values. The current guidelines cause a significant
burden and cost to endoscopy units and necessitate patients
having repeated unpleasant procedures even when up to 50%
may still not have developed oesophageal varices 10 years
after the initial diagnosis [2].
If it were possible to predict oesophageal varices by
noninvasive means this would restrict testing to the popu-
lation deemed to be at most risk and reduce the number
of endoscopies required. Such a screening test should be
simple, quick, reproducible, and cost eﬀective. The utility of
current noninvasive tests to predict oesophageal varices will
be reviewed in this paper.
2. Current Perspectives:
Possible Approaches to Noninvasive
Diagnosis of Oesophageal Varices
2.1. Physical Examination and Laboratory Parameters. Sev-
eral studies have examined the usefulness of diﬀerent clinical
and laboratory parameters as predictors of the presence or
size of oesophageal varices. These are discussed below.
2.1.1. Physical Signs and Variables Related to Liver Function.
A number of clinical signs and other laboratory markers
have been identified either alone or in combination as factors
predicting the presence of oesophageal varices. These include
the presence of spider naevi, splenomegaly or ascites, Child-
Pugh classification, serum albumin, and prothrombin time.
Spider naevi, a low-albumin and low-platelet count were
shown to be independent risk factors for the presence of
varices in a study by Garcia-Tsao et al. [17]. In a further
study by Berzigotti et al. [18], spider naevi, ALT, and albumin
were found to predict oesophageal varices with the best
cutoﬀ giving a sensitivity of 93%, specificity of 37%, and
correctly classifying 72% of patients. Similarly, spider naevi
have been found to be predictive of large oesophageal varices
with a diagnostic accuracy of 72% when using the variables
platelet count, prothrombin index, and spider naevi [19].
Chalasani et al. [20] found that splenomegaly detected on
clinical examination was an independent risk factor for the
presence of large varices. Zaman et al. [21] demonstrated
that cirrhotic patients in Child-Pugh classes B or C were
almost 3 times as likely to have oesophageal varices or large
oesophageal varices as compared to patients in Child-Pugh
class A.
The Baveno IV International Consensus Workshop on
methodology of diagnosis and treatment concluded that
no study reached a high enough level of significance to
warrant the widespread use of such noninvasive markers of
oesophageal varices [13].
2.1.2. Variables Related to Liver Fibrosis. Chronic liver injury
and inflammation leads to fibrosis and ultimately cirrhosis,
through the deposition of extracellular matrix (ECM) com-
plexes. The collagen fibrils of the complex undergo secondary
processing, becoming cross-linked, which confers resistance
to degradative enzymes and irreversibility [22]. Normally,
deposition of the ECM is a dynamic, reversible process
with removal of ECM mediated by several specific matrix
metalloproteinases (MMPs), which in turn are regulated
by soluble inhibitors termed TIMPs (tissue inhibitor of
metalloproteinase). A number of serum markers for ECM
deposition and removal have been evaluated as candidate
markers for liver fibrosis, and a small number of studies
have evaluated their usefulness in predicting oesophageal
varices. Potential markers examined to date include the
glycoproteins, hyaluronic acid and laminin, and members
of the collagen family including procollagen III and type IV
collagen. Conflicting results have been demonstrated. Galal
et al. [23] assessed the ability of serum hyaluronic acid to
predict medium-to-large oesophageal varices and showed
the sensitivity, specificity, positive and negative predictive
values, and diagnostic accuracy at a cutoﬀ of 207 μg/L to be
94%, 77.8%, 88.7%, 87.5%, and 88.3%, respectively. Ko¨rner
et al. [24] showed no association between concentrations of
hyaluronic acid or laminin and grade of oesophageal varices,
and a further study by Bahr et al. [25] confirmed the lack of
association of serum laminin to size of oesophageal varices.
Similar conflict is seen when examining the evidence with
regard to the role of the collagens. In the first of only 2
studies in this area, the aminoterminal propeptide of type
III procollagen was shown to have a weak correlation to
the degree of oesophageal varices [26]. The second study by
Mamori et al. [27] included 44 patients with alcoholic liver
disease and demonstrated a significant diﬀerence in serum
type IV collagen levels between patients with and without
varices (712.3 versus 404.3 ng/mL, P < 0.001), giving an
AUROC of 0.78 for predicting the presence of oesophageal
varices.
None of the aforementioned markers could currently be
utilised to predict oesophageal varices in portal hyperten-
sion; in view of this several diﬀerent biomarkers have been
combined with the aim of improving their diagnostic ability.
FibroTest is a composite score generated by combining the
results of five serum blood tests (alpha-2-macroglobulin,
apolipoprotein A1, haptoglobin, γ-glutamyltranspeptidase,
and bilirubin and alanine) corrected for the age and gender
of the patient. Results have shown high predictive values
for significant fibrosis in patients with chronic hepatitis
C, chronic hepatitis B, fatty liver disease, and chronic
alcoholic liver disease [28–31]. A single study has assessed
the predictive value of fibroTest in the diagnosis of large
oesophageal varices in 99 cirrhotic patients [32]. Significant
diﬀerences in FibroTest value (0.89 versus 0.82), platelet
count (110 versus 150), and prothrombin time (50 versus
66%) were seen between patients with and without large
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oesophageal varices. FibroTest had the highest discriminative
power of all the variables with an AUROC curve of 0.77.
Using a cutoﬀ of 0.80, this gave a sensitivity of 92%,
specificity 21%, PPV 33%, and NPV 86%. A fibroTest score <
0.75 was found to be associated with the absence of large
oesophageal varices with a NPV of 100%. The limitations
to the study are that it was a retrospective study with
significant population bias and has not been reproduced in
a prospective study of compensated cirrhotics. FibroTest is
not readily available to most clinicians, which limit its utility
as a screening test.
2.1.3. Variables Related to Portal Hypertension and Hypersple-
nism. Thrombocytopenia may occur in portal hypertension-
induced splenomegaly, in part due to platelet sequestration,
and a large number of studies have been performed assessing
the relationship between platelet count and oesophageal
varices [17, 19–21]. A low-platelet count is regularly
identified as predictive of oesophageal varices and large
oesophageal varices, but there is a wide variation in the cut-
oﬀ level of platelets used, ranging from 68,000 to 160,000
with sensitivities ranging from 71–90% and specificities from
36–73%. Bias is likely to account for much of this variation,
with the majority of studies being retrospective in nature,
having heterogeneous cohorts of patients resulting in both
selection and spectrum bias.
A longitudinal study by Qamar et al. [33] of 213 patients,
with compensated cirrhosis with portal hypertension but
without varices, demonstrated that the median platelet
count at the time of occurrence of varices was 91,000.
However, no platelet count could be identified that accurately
predicted the presence of oesophageal varices (AUROC curve
0.63), and they, therefore, concluded that platelet count
is an inadequate noninvasive marker for prediction of the
presence of oesophageal varices. In an attempt to improve the
predictive value of the platelet count, it has been combined
with other variables, and the results of these studies are
discussed below.
Oesophageal collaterals develop as a consequence of
portal hypertension, being formed by vascular remodelling
and angiogenesis. Key molecules thought to be involved in
this include nitric oxide and vascular endothelial growth
factor (VEGF). A single study of 85 cirrhotic patients
examined the predictive capability of serum nitrate levels
to detect oesophageal varices [34]. Significant diﬀerences
in serum nitrate levels were found between patients with
large oesophageal varices compared to patients without
oesophageal varices (P < 0.01). The best cut-oﬀ level
for prediction of oesophageal varices was 38 μmol/L, giv-
ing a sensitivity 86.5%, specificity 83.3%, PPV 95%, and
NPV 62.5%. Animal studies suggest that the formation
of oesophageal varices results not only from opening up
of preexisting collateral vessels but also as a result of
angiogenesis which may in part be mediated by VEGF.
Use of VEGF as a noninvasive biomarker has only been
investigated in a single study, and no correlation between
VEGF levels and grade of oesophageal varices was detected
[35].
The development of portosystemic collaterals and the
resultant shunting is responsible for the complication hepatic
encephalopathy, in which ammonia plays a role. One study
has examined the role of blood ammonia concentrations
in the noninvasive detection of oesophageal varices [36]. In
this study of 153 cirrhotic patients, a significant correlation
was demonstrated between oesophageal variceal grade and
venous ammonia levels (r = 0.43, P < 0.001). The AUROC
curve for predicting the presence of oesophageal varices was
0.78, and using a cut-oﬀ of 42 μM/L this gave a sensitivity of
92% and a specificity of 60%.
Therefore, variables associated with portal hypertension
and hypersplenism are not accurate enough to be used as
noninvasive markers of oesophageal varices.
2.1.4. Predictive Scores
(1) Platelet Count/Spleen Diameter Ratio. This ratio is
calculated by dividing the platelet number/mm
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by the
maximum spleen bipolar diameter in mm as estimated by
abdominal ultrasound. There have now been a number of
studies assessing this. The first by Giannini et al. in 2003,
reported the platelet count/spleen diameter ratio to be the
only independent variable associated with presence of OV
on multivariate analysis and identified a cut-oﬀ value of
909, giving a PPV of 96% and NPV of 100% [37]. The
second part of the study confirmed the reproducibility of
this cut-oﬀ level with a PPV of 74% and NPV of 100%
in compensated cirrhotic patients. The same group then
followed up 68 patients without OV with repeat endoscopy
and calculation of the platelet/spleen diameter ratio. At
followup, patients with a platelet count/spleen diameter ratio
<909 had 100% NPV and 84% PPV, and they concluded that
the platelet count spleen diameter ratio was eﬀective in ruling
out the presence of OVwhen cirrhotic patients were followed
longitudinally. Subsequently, a multicentre, international
validation study using the 909 ratio was performed in 218
patients [38]. The test performed less well than in the original
study with a PPV of 76.6% and a NPV of 87.0%. This has
been a consistent feature in all studies subsequently per-
formedwhich vary from being retrospective or prospective in
nature and utilise diﬀerent cut oﬀ points [39–43]. Therefore,
despite promising early results the platelet count/spleen
diameter ratio is not a reliable tool to screen for oesophageal
varices.
(2) Platelet Count and Child-Pugh Class. In 2007, Burton
et al. published the validation of a model for predicting size
and presence of varices based upon platelet count and Child-
Pugh class [44]. The first model aimed to detect large varices
in Child-Pugh A patients with a platelet count <80 and had a
sensitivity of 58%, specificity 79%, PPV 30%, and NPV 92%.
The second model aimed to identifying any varices in Child
B/C patients with a platelet count <90 and had a sensitivity
of 60%, specificity of 59%, PPV 80%, and NPV 34%. Once
again, the performance of these models would not reliably
predict the presence of oesophageal varices.
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(3) AST/ALT Ratio. The AST/ALT ratio has been used to
predict cirrhosis, and by natural extension studies have been
performed to assess its usefulness in predicting oesophageal
varices. In a retrospective study [45], significantly higher
AST/ALT ratios were seen in patients with varices compared
to those without (ratio: 1.8 versus 1.0, P < 0.0001). A further
prospective study [46] found an AST/ALT ratio > 1.12 to be
significantly associated with the presence of varices at initial
endoscopy (OR 3.9, P = 0.02 95% CI 1.3–11.8). This cutoﬀ
gave a sensitivity of 47.8%, specificity of 87%, PPV 42.3%,
and NPV 89.2%, and an AUROC of 0.69. A further study
using a diﬀerent cut-oﬀ of ≥1.0 demonstrated a sensitivity
of 68%, specificity of 89%, PPV 77%, and NPV 83%, with
an AUROC 0.83 (0.72–0.94) for predicting the presence
of oesophageal varices [47]. For the prediction of large
oesophageal varices, this gave a sensitivity 68%, specificity
77%, PPV 41%, and NPV 92%, and AUROC 0.79 (0.64–
0.94). Overall, the AST/ALT ratio correctly classified 81%
patients for the detection of varices and 76% of those with
large varices. Therefore these studies, which include patients
with diﬀerent aetiologies of liver disease and used diﬀerent
cutoﬀs for the AST/ALT ratio cannot confidently predict the
presence of oesophageal varices in clinical practice to avoid
screening all cirrhotic patients with endoscopy.
(4) Right Lobe Liver Albumin Ratio. This ratio is calculated
by dividing the right liver lobe diameter (as assessed by
abdominal ultrasound and measured in millimetres) by the
serum albumin concentration (g/L). This has been assessed
in a single study of 94 cirrhotic patients [48]. Right liver
lobe/albumin ratio correlated with presence and size of
oesophageal varices (r = 0.488, P < 0.01; r = 0.481,
P < 0.01, respectively). For a cut-oﬀ value of 4.425 this gave
a sensitivity of 83.1% and specificity 73.9% and thus once
again cannot be used as a reliable screening test.
2.2. Transient Elastography
2.2.1. Liver Stiﬀness. Transient elastography (TE, FibroScan,
Echosens, France) is a noninvasive technique developed
to assess hepatic fibrosis in patients with chronic liver
diseases. Fibrosis causes an increase in liver stiﬀness, and
measurement of this forms the basis of TE, which is painless,
rapid, and easy to perform. Studies suggest that TE is highly
reproducible and reliable with very high interobserver and
intraobserver agreement overall but that patient related and
liver disease related factors may have a negative eﬀect on
the reproducibility of this technique [49]. A wide range of
liver stiﬀness values have been reported ranging from 2.5 to
75 kPa, being influenced by gender, body mass index, disease
aetiology, and presence of necroinflammatory change [50–
53]. As a rough guide, normal TE values are considered to
be 3.8–8 kPa in men and 3.3–7.8 kPa in women, significant
fibrosis (Metavir fibrosis stage≥ 2) 7-8 kPa and cirrhosis 13–
17 kPa.
A number of studies have been performed examining
the relationship of liver stiﬀness to size and presence of
oesophageal varices, and these results are summarised in
Table 1 [47, 54–57]. These studies demonstrate a significant
correlation between liver stiﬀness measurements and the
presence of oesophageal varices but are divided with regard
to the relationship of liver stiﬀness to variceal size.
For the diagnosis of variceal presence, AUROC curves
varied from 0.76–0.85, with a sensitivities of 84–95%, speci-
ficities of 43–78%, PPV 57–89%, and NPV 66–91% using
cutoﬀs between 13.9–21.5 kPa. For the diagnosis of large
oesophageal varices, AUROC varied from 0.76–0.87, with
sensitivities of 77–91%, specificities of 60–85%, PPV 48–56%
and NPV 94-95% using cut-oﬀs between 19–30.5 kPa. The
other limitations of the study relate to inclusion of patients
with liver disease of diﬀerent aetiologies and of diﬀerent
severity, according to Child-Pugh class.
The study by Castera et al. best represents the cohort
of patients in whom noninvasive screening for varices is
needed [47]. All 70 patients were Child-Pugh class A and
had cirrhosis secondary to hepatitis C. They demonstrated
that LSM values increased with the grade of OV (P < 0.001).
The AUROC for presence of OV was 0.84 and 0.87 for large
OV. A cutoﬀ of 21.5 kPa predicted the presence of OV with
a sensitivity of 76%, specificity 78%, PPV 68%, and NPV
84% and correctly classified 73% of patients. At a cutoﬀ
of 30.5 kPa, the presence of large OV was predicted with a
sensitivity 77%, specificity 85%, PPV 56%, and NPV 94%,
and correctly classified 79% of patients.
Therefore, the predictive performance of liver stiﬀness
measurement is poor for the diagnosis of OV with low
specificity and PPV, particularly with regard to large OV.
However, it may be useful as a screening test to identify
patients in whom variceal screening is not required, but at
present cannot be advocated as a surrogate for gastroscopy.
2.2.2. Spleen Stiﬀness. Transient elastography has also been
used to determine spleen stiﬀness, using the hypothesis
that splenomegaly resulting from portal hypertension causes
changes in the spleen’s density. In a study of 191 patients
(135 cirrhotic) recently published, it was demonstrated
that spleen stiﬀness was significantly higher in cirrhotics
than noncirrhotics and in patients with oesophageal varices
compared to those without [58]. 52.5 kPa was determined
to be the best cutoﬀ giving an AUROC curve of 0.74. They
found a better diagnostic accuracy, of 89.95%, in predicting
the presence but not the grade of oesophageal varices when
liver and spleen stiﬀness were used together.
MR Elastographic spleen stiﬀness has also been assessed
in a small study of 17 compensated cirrhotics. All of the
7 patients with oesophageal varices had a mean spleen
stiﬀness of >10.5 kPa [59]. Further larger studies are needed
to investigate the diagnostic accuracy of MR Elastographic
spleen stiﬀness for noninvasive prediction of oesophageal
varices.
2.3. Other Imaging Modalities
2.3.1. Ultrasound. Doppler ultrasonography (US) imaging
provides a real-time, inexpensive, and repeatable examina-
tion of the portal system and allows estimation of both
International Journal of Hepatology 5
Table 1: Summary of diagnostic accuracy of LSM for the detection of oesophageal varices (OV) or large varices (LOV). TE: transient
elastography.
Diagnostic performance of TE
for the diagnosis of OV by
Author
[54] [55] [56] [57] [47]
Number of pts 165 61 (47 cirrhotic) 150 (89 cirrhotic) 112 298 (70 cirrhotic)
Aetiology Mixed (HCV predominant) HCV Mixed Mixed HCV
Prevalence OV 45% 64% 72% 36%
Proposed cutoﬀs for
presence of OV/LOV
OV 13.1
LOV 19
17.6
OV 21.1
LOV 29.3
19.7
OV 21.5
LOV 30.5
Sensitivity (%) 95/91 90 84/81 87 76/77
Specificity (%) 43/60 43 71/61 70 78/85
PPV (%) 57/48 77 89 68/56
NPV (%) 91/95 66 66 84/94
AUROC 0.84/0.83 0.76 0.85/0.76 0.818 0.84/0.87
arterial and venous flow. It is considered the first-line
imaging technique in patients with cirrhosis. Portal vein
diameter, portal blood velocity and congestion index, spleen
size, flow pattern in the hepatic veins, and the presence of
abdominal portosystemic collaterals are all US parameters
previously thought to have with prognostic significance but
all with poor sensitivity and specificity [60]. One large study
proposed prothrombin activity of less than 70%, portal vein
diameter greater than 13mm, and platelet count < 100 ×
109 as noninvasive predictive tools to discriminate cirrhotic
patients with and without oesophageal varices (OV) [61].
The ROC curve constructed from all possible combinations
of these dichotomous variables initially looked promising
with an area under the curve (AUC) value of 0.80. To assess
the validity of this tool, the investigators used a matched
second cohort where the positive predictive value was found
to be significantly reduced [62]. A further validity study was
repeated in another centre with a similarly poor sensitivity
and specificity [63]. Thus, US has limited specificity and
cannot replace endoscopy as a screening tool for large
oesophageal varices [61, 63].
2.3.2. CT. Three recent studies suggest that multidetector
CT is comparable to upper endoscopy in detecting small
and large varices [64–66]. Only two of these studies were
carried out prospectively [64, 65], and only one included
a cost analysis [64]. In one of the previous studies, vir-
tual oesophagography could be carried out using the CT
scans, but this procedure requires time-consuming and
invasive intubation of the oesophagus with a catheter for
air insuﬄation [66]. CT was found to have approximately
90% sensitivity in the identification of oesophageal varices
determined to be large on endoscopy, but only about 50%
specificity. The sensitivity of CT detecting gastric varices was
87%. In addition, a significant number of gastric varices,
perioesophageal varices and extraluminal pathology were
identified by CT that were not identified by endoscopy. Use
of CT as the initial screening modality for the detection
of varices was significantly cost eﬀective compared to
endoscopy irrespective of the prevalence of large varices [64].
Patients overwhelmingly preferred CT over endoscopy in all
three studies. One of the major limitations identified in all
studies was the diﬀering rates of interobserver agreement
in variceal size of both modalities, with only one study
finding agreement between radiologists being higher than
between endoscopists [64]. How reproducible this model
could, therefore, remain unproven. There are also major
concerns over the risk of cumulative radiation exposure in
prolonged screening programmes [67].
2.4. Capsule Endoscopy. New capsule endoscopy devices have
been developed, specifically for use in the oesophagus,
acquiring images from both ends of the device. Several stud-
ies have been performed, assessing the ability of these capsule
endoscopy devices to detect any varices and identify large
varices requiring primary prophylaxis [68–73]. Conventional
OGD was used as the gold standard.
With regards to the detection of varices, sensitivity
varied between 68–100%, and specificity 86–100% [70–72,
74]. In the largest study performed to date, 288 patients
were recruited in a multicentre trial [68]. Conventional
OGD identified OV in 180 patients (62.5%) and capsule
endoscopy identified OV in 152 of these, giving a diﬀerence
in diagnosing OV of 15.6% in favour of OGD. In 13 cases
(14.5%), varices were identified by capsule but not confirmed
by OGD. Overall agreement for detection of varices was
85.8%, with a sensitivity of 84%, specificity 88%, positive
likelihood ratio 7.0, and negative likelihood ratio 0.18.
With regard to the grading of varices, there was complete
agreement on the grade in 79%. In diﬀerentiating between
varices requiring treatment or not, the sensitivity, specificity,
PPV, and NPV for capsule endoscopy were 78%, 96%,
87%, and 92%, respectively. Overall agreement on treatment
decisions based on variceal size was 91% (kappa = 0.77).
Other studies have correctly identified patients requiring
primary prophylaxis in 74–100% of patients [69, 71, 72,
74]. 2 meta-analyses produced similar results with pooled
sensitivities of 83% and 83.8% and pooled specificities of
85% and 80.5%, respectively for the diagnosis of oesophageal
varices [75, 76].
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Capsule endoscopy is reported to be feasible in 94–
99% of patients with the main reasons for failure being
because patients were unable to swallow the capsule or due
to technical problems with the recording or function of the
capsule. Adverse events have been reported in 0–1.4% of
cases, including episodes of capsule retention necessitating
removal. Tolerability of the capsule is found to be better than
conventional OGD, with better preprocedure perception and
postprocedure satisfaction. 26–83% patients prefer capsule
endoscopy over conventional OGD in the studies performed
to date [68–70, 72–74, 77].
With regard to cost-eﬀectiveness, 2 studies have been
performed, the first concluding that both screening methods
are equivalent, the second that screening with capsule
endoscopy followed by beta-blocker therapy may be cost-
eﬀective compared to OGD followed by beta-blocker therapy
but is highly sensitive to local costs [78, 79].
Therefore in summary, capsule endoscopy is feasible
in the majority of patients and with regard to patient
preference, capsule endoscopy appears to be preferable
to conventional endoscopy and may improve compliance
with screening programmes, although this remains to be
determined. The jury is still out with regard to cost but when
it comes to performance, conventional OGD remains the
gold standard.
3. The Future Approach to Noninvasive
Detection of Oesophageal Varices
Cirrhosis and portal hypertension are characterized by the
development of a hyperdynamic circulation with elevated
cardiac output and stroke volume and reduced systemic
vascular resistance [80]. These haemodynamic variables
are independently associated with portal pressure and size
of oesophageal varices [81–84]. Measurement is tradi-
tionally invasive, the thermodilution technique requiring
introduction of a catheter into the pulmonary artery. A
noninvasive method for assessing systemic haemodynamics
may allow noninvasive detection of oesophageal varices.
New techniques are now available that measure systemic
haemodynamics noninvasively. The Finometer (Finapres
Medical Systems, Amsterdam, The Netherlands) is a non-
invasive device that allows continuous beat-to-beat blood
pressure and haemodynamic monitoring over a number
of hours [85]. We have demonstrated the presence of
the hyperdynamic circulation using this technique and
shown significant diﬀerences in cardiac output and systemic
vascular resistance according to the size of oesophageal
varices. We have also shown significant correlation of these
haemodynamic variables to the 1-year probability of variceal
bleeding. Data as yet unpublished examining the predictive
ability of noninvasive parameters has shown promising
initial results, with an AUROC curve of 0.86 for cardiac
output and 0.77 for peripheral vascular resistance for the
diagnosis of large oesophageal varices. Optimal cutoﬀs for
these haemodynamic parameters remain to be defined.
Considering a cutoﬀ of 7.06 L/min for cardiac output, this
gave a sensitivity of 91% and a negative predictive value
of 93%, maintaining a diagnostic accuracy of 86%. Using
a cutoﬀ of 0.99MU for peripheral vascular resistance gave
a sensitivity of 91% and negative predictive value of 91%.
These initial results require further investigation.
Proteomics is the large-scale study of proteins, particu-
larly their structure and function and interactions in a bio-
logical system. Proteomics does not require prior knowledge
of the proteins present and, therefore, is ideal to screen for
the best biomarkers of disease. Promising results have been
seen in patients with liver cirrhosis to search for markers of
hepatic fibrosis [86–88] and has been demonstrated to be
more accurate than fibroTest. The optimal biomarker needs
to be able to predict clinically significant endpoints as well
as liver histology, and so further research is needed to know
whether proteomics will ever be useful in the noninvasive
diagnosis of oesophageal varices.
The major significant endpoint with regard to varices
is that of bleeding. The evidence shows that infection and
variceal bleeding are related [89]. In experimental cirrhosis,
bacterial products increase portal pressure by activating
macrophages and releasing vasoconstrictive prostaglandins
[90–92]. Soluble CD163 in serum is a new specific marker
of macrophage activation. A recent study demonstrated
that sCD163 is increased in cirrhosis, levels correlating
with portal pressure, but that levels do not drop following
reduction of portal pressure after transjugular intrahepatic
portosystemic shunt [93]. Therefore, chronic activation of
these cells may play a role in establishing and maintaining
portal hypertension. Further work is needed to assess their
potential not only as a noninvasive marker of oesophageal
varices but of varices with the highest bleeding risk.
4. Conclusions
In conclusion, based on all the available evidence to date,
upper GI endoscopy remains the gold standard for the
diagnosis of oesophageal varices in cirrhotic patients despite
its own limitations. Clinical, biochemical, and radiological
parameters currently are not accurate enough to avoid
screening endoscopy, due to the risks associated with missing
patients with large oesophageal varices. A screening test must
be simple and inexpensive, and therefore current promising
tools such as CT scanning or capsule endoscopy which are
highly acceptable to patients may not prove to be cost-
eﬀective or suitable for repeated measurement. Assessment
of systemic haemodynamics and other serum markers may
hold promise for the future, and more studies are needed to
better understand and identify high risk groups, which may
in time be facilitated by proteomic approaches.
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